Vaccination Cuts Risk for Myocardial Infarction, Stroke After COVID-19
Findings show lower hospitalization risk 31 to 120 days after COVID-19 infection
Findings show lower hospitalization risk 31 to 120 days after COVID-19 infection
Sotagliflozin is an investigational dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) inhibitor.
Abelacimab is a highly selective, fully human monoclonal antibody designed to inhibit both factor XI and its activated form, factor XIa.
In Mendelian randomization analyses, 25(OH)D associated with risk for dementia, but not stroke or neuroimaging outcomes
VLX-1005 is a first-in-class, selective small molecule inhibitor of 12-lipoxygenase, a key target within the arachidonic acid pathway.
DCDs noninferior to non-DCDs for survival among older adults who underwent femoropopliteal artery revascularization
Teva is voluntarily recalling a single lot of Anagrelide Capsules, USP 0.5mg, due to dissolution failure that was detected during a routine stability test.
Some in-hospital therapies and prophylactic treatments may confer no benefit or are potentially harmful and should be reconsidered
Consumption of three to five versus zero cups of espresso linked to increased S-TC in women and men, with greater increase for men
These recommendations only apply to individuals who do not have a history of CVD and are not already taking daily aspirin.